Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
By Dr. Matthew Watson
RADNOR, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the 43rd Annual J.P. Morgan Healthcare Conference.
Read the original:
Certara to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning
By Dr. Matthew Watson
Due to the closure of the Securities and Exchange Commission and U.S. stock markets on January 9, in honor of the late former President Jimmy Carter, Tilray has moved its earnings announcement to January 10 Due to the closure of the Securities and Exchange Commission and U.S. stock markets on January 9, in honor of the late former President Jimmy Carter, Tilray has moved its earnings announcement to January 10
Read the rest here:
Tilray Brands Moves Earnings Date to January 10, 2025, in Observance of the National Day of Mourning
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
By Dr. Matthew Watson
LOS ANGELES, Jan. 02, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced it will host a virtual investor event on Monday, January 6, 2025 at 4:30 PM ET to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential for a best-in-class efficacy and safety profile in Thyroid Eye Disease (TED). The event will also feature external clinician perspectives on the continuing unmet needs in TED and disclose the design for the Phase 3 LONGITUDE program, which was developed following a successful End-of-Phase 2 meeting with the FDA to be the most inclusive registrational program to date in TED. To register, click here.
See the original post here:
ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
By Dr. Matthew Watson
STAMFORD, Conn., Jan. 03, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that Saqib Islam, Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 11:15 a.m. PT.
Continue reading here:
SpringWorks Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
By Dr. Matthew Watson
DEER PARK, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired Galzin® (zinc acetate).
Read the rest here:
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
By Dr. Matthew Watson
CAMBRIDGE, Mass., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that its management team is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 7:30 a.m. PT / 10:30 a.m. ET.
Read more here:
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
By Dr. Matthew Watson
CONSHOHOCKEN, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025 at 2:15 pm PT. The presentation will be webcast live and can be accessed here or by visiting Madrigal’s Investor Relations Site, Events and Presentations.
Read more:
Madrigal Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
By Dr. Matthew Watson
DUBLIN, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 4:30 p.m. ET on Wednesday, January 8, 2025, to provide a corporate update and discuss the Company's preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2024.
Continued here:
Avadel Pharmaceuticals to Provide a Corporate Update and Preliminary Fourth Quarter and Full Year 2024 Financial Highlights on January 8
Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc.
By Dr. Matthew Watson
Energroup to acquire a revenue-generating company and remove its "shell" status Energroup to acquire a revenue-generating company and remove its "shell" status
Read more from the original source:
Energroup Holdings Corp (OTC: ENHD) to Acquire Cocannco Inc.
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
By Dr. Matthew Watson
David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO David Lazar agrees to invest $3.1 million in Preferred Stock and becomes Interim CEO
See the article here:
Cyclacel Pharmaceuticals Announces Agreement for the Acquisition of Preferred Stock by David Lazar
VALNEVA Declaration of shares and voting rights: December 31, 2024
By Dr. Matthew Watson
To Read More: VALNEVA Declaration of shares and voting rights: December 31, 2024Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
By Dr. Matthew Watson
Media ReleaseCOPENHAGEN, Denmark; January 03, 2025Genmab A/S (Nasdaq: GMAB) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 14, 2025, 12:00 AM CET on January 15, 2025.?The live and archived webcast of the presentation will be available on Genmab’s website at?https://ir.genmab.com/events-presentations.
Continued here:
Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Procaps Group Receives Additional Delinquency Letter
By Dr. Matthew Watson
MIAMI and BARRANQUILLA, Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated LatAm healthcare and pharmaceutical services company, today announced that, as anticipated, on December 31, 2024, the Company received notice from The Nasdaq Stock Market LLC (“Nasdaq”) of an additional filing delinquency relating to the Company’s interim financial statements for the period ended June 30, 2024.
Continued here:
Procaps Group Receives Additional Delinquency Letter
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
By Dr. Matthew Watson
VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics, Inc. (TSX: RKV), a biopharmaceutical company focused on the development of new cancer therapies based on novel DNA-damage response technologies, is pleased to announce its participation in events and meetings being held alongside the 43rd Annual J.P. Morgan Healthcare Conference, taking place January 13-16, 2025, in San Francisco.
Read the original post:
Rakovina Therapeutics to Connect with Industry Leaders During 43rd Annual J.P. Morgan Healthcare Conference Week
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
By Dr. Matthew Watson
LAKE FOREST, Ill., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (NASDAQ: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, announced that effective December 23, 2024, the Compensation Committee of the Company’s Board of Directors granted Mary Pietryga, the Company’s newly-hired Senior Vice President, Chief Commercial Officer, 62,500 restricted stock units (“RSUs”) and 275,000 stock options (“options”).
See more here:
Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
By Dr. Matthew Watson
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company’s Annual General Meeting of Shareholders (the “Meeting”), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed Meeting. The Meeting has been postponed due to delays stemming from the disruption in postal service in Canada, and to provide further time to solicit proxies from the Company’s shareholders.
Read the rest here:
BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025
BriaCell Announces Proposed Effective Date of Share Consolidation
By Dr. Matthew Watson
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company’s board of directors has approved the consolidation (the “Consolidation”) of the Company’s issued and outstanding common shares (the “Common Shares”) on the basis of one (1) post-Consolidation Common Share for every fifteen (15) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq Capital Market (the “Nasdaq”).
View original post here:
BriaCell Announces Proposed Effective Date of Share Consolidation
PharmaTher Announces Grant of Stock Options
By Dr. Matthew Watson
TORONTO, Jan. 03, 2025 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company, announces that it has granted a total of 800,000 stock options to two of the three directors of the Company at an exercise price of $0.22 per share. The stock options vest immediately on the grant date and have a five-year term, expiring January 2, 2030. The Chairman and CEO, Fabio Chianelli, did not receive stock options.
See the rest here:
PharmaTher Announces Grant of Stock Options
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
By Dr. Matthew Watson
Carlsbad, CA, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that it had made an equity grant to a new employee under its 2021 Inducement Plan, as amended.
Read the original here:
Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Oculis Publishes Notification of Major Changes in Voting Rights
By Dr. Matthew Watson
ZUG, Switzerland, Jan. 04, 2025 (GLOBE NEWSWIRE) -- Attached is a Notification of Major Changes in Voting Rights, in relation to Brunnur vaxtarsjóður slhf‘s distribution of its shares in Oculis Holding AG to Brunnur Vaxtarsjóður slhf‘s shareholders.
Go here to read the rest:
Oculis Publishes Notification of Major Changes in Voting Rights